The global market for human antifungal therapeutics reached nearly $11.6
billion in 2012 and $11.8 billion in 2013. This market is expected to grow to
nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2%
over the five-year period from 2013 to 2018.

This report provides:

An overview of the global market for human antifungal therapeutics

Analyses of global market trends, with data from 2012, estimates for 2013,
and projections of compound annual growth rates (CAGRs) through 2018.

Identification of new antifungal research, development, and drug
applications

Information on over the counter (OTC) vs. prescription products

Comprehensive profiles of leading companies in the industry.

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The goal of BCC Research in conducting this study was to determine the current
status of the global human antifungal market and assess its growth potential
over the five-year period from 2013 to 2018. This report covers approved human
therapeutics, with a heavy focus on therapeutics in early development. These
new molecular and biological entities are from traditional pharmaceutical
sources, naturally derived synthetic chemicals and biological sources as well
as the "herbal natural folk medicine" marketplace. If an approved or
well-known medicine is being studied in combination with another molecular
entity, it is considered a new therapy and often has been included for review.
New drug and patent applications are presented as the study focuses on new
methods of drug administration, drug clinical trials, and discovery and
development.

It should be noted that there is a strong emphasis on early research due to
the critical need for new and more effective medicines; hence, BCC Research is
including a section of medicines intended for human utilization that are in
clinical testing as well as information on new and novel in vitro therapies.
Greater than 98% of medicines at the preclinical level are terminated prior to
their utilization in humans, and the research in this area is vast. We are
limiting this research to therapies that depict a positive result or that
represent a very rare and novel approach worthy of further review from R&D
groups.

Our key objective in this report is to present an in-depth analysis of the
current human antifungal market and to explore its future direction. In the
last five years there has been a decrease in the number of patent applications
filed in this area. Between 1990 and 1999 there were six U.S. patents
granted-evidence of the evolution of drug resistance and an increasing
mortality rate.[1],[2]

REASONS FOR DOING THIS STUDY

Fungi are highly resistant microbiological eukaryotic microorganisms. In other
words, they are becoming drug-resistant to the approved compounds and some
therapies later in clinical development. The therapies are designed to
eradicate these fungi through the various antifungal mechanisms of action,
such as disrupting reproductive capabilities, destroying cell walls or
modifying fungal DNA and cell functioning. It is a given fact that
infestations in humans, animals, plants and the environment are on the rise,
with many having lethal consequences in both the immunocompetent and the
immunocompromised. That being the case, BCC Research was particularly
interested in examining the antifungal market growth of developing products
depicting efficacy. We are including data regarding the market shift for those
products that are now relegated to over-the-counter (OTC) status that
previously had only been provided by prescription; moreover, we will identify
new antifungal research, development, new drug applications and novel
approaches to the market.

Previously, BCC Research examined the antifungal market in its 2003 report,
PHM029A The Market for Antifungal Drugs, in PHM029B Global Markets for
Antifungal Agents and in PHM029C Antifungal Drugs: Technologies and Global
Markets. Due to the rapidly changing market, BCC Research chose to reexamine
the marketplace through another analysis and project its new growth potential.
Additionally, PHM029A focused only on human fungal diseases and associated
antifungals; PHM029B incorporated the marketplace for antifungals in the
veterinary, agricultural and environmental industries; and PHM029C and PHM029D
focused on human therapeutics with an intensive focus on human therapeutics in
the developmental pipeline. PHM029E is an update of PHM029D.

INTENDED AUDIENCE

This report was prepared as a study of the global antifungal marketplace based
on fungal infections and infestations with a focus on human therapeutics.
Information is presented on the antifungal industry in general, specific
pharmaceuticals and chemical agents, new technology within the market, new and
novel drug applications and market-related issues. In many cases actual
revenue is given for the period of 2012 and 2013, with projections of trends
and compound annual growth rates (CAGRs) 2013 through 2018.

This study will be of significant interest to hospitals, pharmacies,
pharmaceutical companies, biopharmaceutical researchers, pharmaceutical
company directors and marketing executives, contract research organizations
(CROs), chemists, physicians, nurses, physician assistants, product managers
and representatives, and all manner of institutional directors ranging from
nursing homes and schools to long-term-care facilities both public and
private. It will also be of interest to biologists and those interested in the
field of mycology.

SCOPE OF REPORT

This study examines human applications both currently marketed and in the
development of antifungal technologies. In an extensive analysis, BCC Research
examines each market segment, presents its current market status and offers
various forecasts for growth over the next five years. Other factors such as
Food and Drug Administration (FDA) restrictions, government legislation,
fungal resistance and changes in consumerism such as a greater demand for OTC
medications and/or natural and alternative remedies are also highlighted. Our
financial and sales analysis focuses on the available figures from 2012 to
2013, with estimates for 2018, including CAGR as a percentage.

METHODOLOGY

Through an extensive industry survey inclusive of online database searches of
industry-specific data sources coupled with financial, trade, government and
marketing database sources as well as interviews via correspondence or
telephone with independent sources comprising companies, government agencies
and academic experts, BCC Research was able to compile data to present our
analysis of the antifungal market by market segment.

INFORMATION SOURCES

Of the companies and agencies surveyed, the majority were pharmaceutical or
compound manufacturers. Additional information was supplied by known industry
or trade sources.

ANALYST CREDENTIALS

Mary Anne Crandall is an expert industry analyst specializing in the
pharmaceutical industry for over 22 years. She has completed several in-depth
studies on various medical topics requiring both medical expertise and
excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive
knowledge in the medical field, has an M.S. in psychology and is currently
working on her Ph.D.